Did you mean excedrin ester strenght?
Displaying drugs 176 - 200 of 896 in total
Methysergide
An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the...
Approved
Matched Categories: … Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Hydroxyzine
Hydroxyzine is a first-generation histamine H1-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine,...
Approved
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
Lomefloxacin
Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) …
Daprodustat
Daprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK.[A254167,A254162] Patients with CKD cannot induce erythropoietin (EPO) production in response to hypoxia or anemia. As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular HIF1α and HIF2α and the induces...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) …
Avapritinib
Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares a...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Medroxyprogesterone acetate
Medroxyprogesterone acetate (MPA) is a progesterone derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Flunisolide
Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors.
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP3A4 Inducers (strength unknown) …
Lorazepam
Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Approved
Matched Categories: … Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Torasemide
Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.
Approved
Matched Categories: … Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Grepafloxacin
Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.
Approved
Investigational
Withdrawn
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) …
Albendazole
A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)
Approved
Vet approved
Matched Categories: … Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Flurazepam
A benzodiazepine derivative used mainly as a hypnotic.
Approved
Illicit
Investigational
Matched Categories: … Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) …
Bepridil
A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United States, as it has been implicated in causing...
Approved
Withdrawn
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
Hydroxyprogesterone caproate
Hydroxyprogesterone caproate is a synthetic steroid hormone that is similar to medroxyprogesterone acetate and megestrol acetate. It is an ester derivative of 17α-hydroxyprogesterone formed from caproic acid (hexanoic acid). Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S. Food and Drug...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2C19 Inducers (strength unknown) …
Lemborexant
Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits,...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2B6 Inducers (strength unknown) …
Ripretinib
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020....
Approved
Matched Categories: … Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) …
Fluvoxamine
Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.
Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Calcitriol
Calcitriol is an active metabolite of vitamin D with 3 hydroxyl (OH) groups and is commonly referred to as 1,25-dihydroxycholecalciferol, or 1alpha,25-dihydroxyvitamin D3, 1,25-dihydroxyvitamin D3. It is produced in the body after series of conversion steps of 7-dehydrocholesterol from exposure to UV light. 7-dehydrocholesterol is converted to DB00169 (vitamin D3)...
Approved
Nutraceutical
Matched Categories: … Cytochrome P-450 CYP3A4 Inducers (strength unknown) …
Phentermine
Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows this agent to...
Approved
Illicit
Matched Categories: … Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Argatroban
Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Bezafibrate
Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) …
Drospirenone
Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with Ethinyl estradiol. Most recently, it was approved by both Health Canada and the FDA in combination with Estetrol as an oral contraceptive therapy.[L33199,L33174] Aside from its contraceptive effects, drospirenone is used with estrogens to...
Approved
Matched Categories: … Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Nevirapine
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
Approved
Matched Categories: … Cytochrome P-450 CYP2C9 Inducers (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Disulfiram
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms...
Approved
Matched Categories: … Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) …
Tolbutamide
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) …
Displaying drugs 176 - 200 of 896 in total